Bristol Myers Squibb filed a WARN notice with the New Jersey Department of Labor on September 22, cutting 265 more positions at its Princeton headquarters. The departures run from December through next May. It’s the company’s third New Jersey WARN round this year: 247 in February, 206 in April, and now 265. That’s 718 positions in 2026 alone. Stretch the count back to 2025 and the state total tops 1,700.
Three filings, three near-identical statements. A BMS spokesperson called it aligning “resources and organizational structure to meet the demands of a rapidly evolving landscape.” CFO David Elkins, on the earnings call, credited “our strategic productivity initiative.” Same language in February. Same language in September. Not once does either statement name artificial intelligence.
Three rounds, one state, 718 people
A single 265-person cut barely registers at a company BMS’s size. Line up all three 2026 filings and the shape changes. February: 247 positions. April: 206. September: 265. Three rounds, averaging one every two months, all inside one state. Widen the window to 2025 and New Jersey’s cumulative BMS layoff total crosses 1,700 — and that’s only the slice a state WARN law forces into public view.
Behind all three rounds sits a bigger number: a $2 billion annual cost-reduction target by the end of 2027, announced in February 2025 and branded internally as the “strategic productivity initiative.” The direction is explicit. Money is moving away from older drugs losing sales and toward the newer pipeline: pre-launch spending on the CELMoD franchise, and pumitamig, the PD-L1xVEGF bispecific BMS is developing with BioNTech. Projected 2026 operating expense sits near $16.5 billion. Which jobs funded that shift, BMS has never specified.
The same silence, one industry over
We covered this exact pattern at Prudential on September 18: three Newark WARN rounds, 196 positions, and a company statement that never once said AI. Bristol Myers Squibb is now a second data point for it, insurance swapped for pharma.
Set it next to what happened one day earlier. On September 21, at its London Capital Markets Day, Novo Nordisk confirmed it has roughly 13,000 fewer full-time employees than a year ago. The same afternoon, on the same stage, its chief scientific officer and head of AI put a number on the slide: clinical study reports now come out 10x faster. Novo’s headcount drop and its AI claim landed in the same presentation, on the same day. Bristol Myers Squibb’s language carries no equivalent claim, nothing more specific than “efficiency” and “resource alignment,” words that fit any reorganization at any company in any industry.
This is a pattern we’ve tracked since May. LinkedIn called its 875-person cut, 5% of staff, “explicitly not AI.” Intuit’s CEO told a reporter its 3,000-role cut, 17% of the company, had “nothing to do with AI.” Both statements at least named something a reporter could push back on. Bristol Myers Squibb doesn’t name anything specific enough to dispute. It just never uses the word.
None of this proves BMS is automating these roles away. The public record doesn’t support that conclusion, and it doesn’t rule it out either. What’s confirmable is the contrast in disclosure. Novo chose to put AI on the record as the thing making its smaller workforce work. Bristol Myers Squibb chose not to use the word at all, wrapping the same category of cut in “resource alignment” instead.
Where the patent cliff points next
The WARN filing doesn’t name departments, and nothing in the public record identifies which team the 265 positions sat in. But BMS’s own stated direction points somewhere specific: budget is coming out of the teams supporting declining older drugs, and it’s being protected, likely expanded, around CELMoD and pumitamig. That reallocation matters more to pharma workers than the headline number does. It describes a pattern playing out industry-wide: legacy-brand commercial teams shrinking, pipeline-adjacent research, regulatory, and launch-readiness roles holding or growing, even as total headcount falls.
718 isn’t an endpoint. It’s the third time in fourteen months a Bristol Myers Squibb cut has landed under 300 people in a single New Jersey filing, each round small enough to stay out of national headlines, each one large enough to trigger a mandatory state disclosure. That’s the same cadence we tracked at Prudential. No single announced “restructuring day,” just a line that hasn’t stopped moving, and a company that has not once, across three filings, used the word AI to explain why.
